New combo aims to stall lung cancer when targeted pills start to fail

NCT ID NCT07669051

Ongoing Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding ivonescimab (an immunotherapy drug) to the current targeted therapy pill can help people with advanced non-small cell lung cancer whose disease is slowly progressing. The study involves 36 adults with a specific EGFR gene mutation. Researchers will measure how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ivonescimab (a drug that helps the immune system fight cancer) combined with an EGFR-TKI (a targeted cancer pill)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease is slowly getting worse on current targeted therapy.
What could go wrong: This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Shandong cancer hospital and institute

Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.